Tong Liu

Dr. Tong Liu

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
TLTong Liu
Tong Liu
SYSheng Yang
Sheng Yang
JSJing Sui
Jing Sui
SXSi‐Yi Xu
Si‐Yi Xu
YCYan‐Ping Cheng
Yan‐Ping Cheng
GLGeyu Liang
Geyu Liang

25 June 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
SYSheng Yang
Sheng Yang
TLTong Liu
Tong Liu
HNHongmei Nan
Hongmei Nan
YWYan Wang
Yan Wang
HCHao Chen
Hao Chen
GLGeyu Liang
Geyu Liang

1 November 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
TLTong Liu
Tong Liu
SYSheng Yang
Sheng Yang
YCYan-Ping Cheng
Yan-Ping Cheng
XKXiao-Ling Kong
Xiao-Ling Kong
DDDan-Dan Du
Dan-Dan Du
GLGeyu Liang
Geyu Liang
Purpose: Gastric cancer (GC) is aggressive cancer with a high mortality rate worldwide. N6-methyladenosine (m6A) RNA methylation is related to tumorigenesis, which is dynamically regulated by m6A modulators (“writer,” “eraser,” and “reader”). We conducted a comprehensive analysis of the m6A genes of GC patients in TCGA datasets to identify the potential diagnostic biomarkers. Materials and Methods: We analyzed the expression profile of m6A genes in the TCGA cohort and constructed a diagnostic-m6A-score (DMS) by the LASSO-logistic model. In addition, by consensus cluster analysis, we identified two different subgroups of GC risk individuals by the expression profile of m6A modulators, revealing that YTHDF1’s expression variation profile in GC diagnosis. We also performed RT-qPCR and WB verification in 17 pairs of GC specimens and paired adjacent non-tumor tissues and GC cell lines, and verified the expression trend of YTHDF1 in five GEO GC datasets. YTHDF1 expression and clinical features of GC patients were assessed by the UALCAN. Results: The DMS with high specificity and sensitivity (AUC = 0.986) is proven to distinguish cancer from normal controls better. Moreover, we found that the expression profile variation of YTHDF1 was significantly associated with the high-risk subtype of GC patients. RT-qPCR and Western blot results are consistent with silicon analysis, revealing that YTHDF1’s potential oncogene role in GC tumor. Conclusion: In conclusion, we developed the m6A gene-based diagnostic signature for GC and found that YTHDF1 was significantly correlated with the high-risk subtype of GC patients, suggesting that YTHDF1 might be a potential target in GC early diagnosis.

9 February 2022 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
TLTong Liu
Tong Liu
CXC. Xu
C. Xu
JDJeffrey B Driban
Jeffrey B Driban
TMT. McAlindon
T. McAlindon
CEC.B. Eaton
C.B. Eaton
BLBing Lu
Bing Lu

17 March 2021 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
CXC. Xu
C. Xu
TLTong Liu
Tong Liu
JDJ.B. Driban
J.B. Driban
TMT. McAlindon
T. McAlindon
CEC.B. Eaton
C.B. Eaton
BLB. Lu
B. Lu

8 April 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
SYSheng Yang
Sheng Yang
JSJing Sui
Jing Sui
TLTong Liu
Tong Liu
WWWenjuan Wu
Wenjuan Wu
SXSiyi Xu
Siyi Xu
GLGeyu Liang
Geyu Liang